Accès ouvert
2025
article
OpenAlex
Lisa Scheiblecker, Thorsten Klampfl, Eszter Doma, Sofie Nebenfuehr et autres
Metabolic reprogramming and cell cycle deregulation are hallmarks of cancer cells. The cell cycle kinase CDK6 has recently been implicated in a wide range of hematopoietic malignancies. We here investigate the role of CDK6 in the regulation of cellular metabolism in BCR::ABL1+ …
at
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Alessia Schirripa, Helge Schöppe, Sofie Nebenfuehr, Markus Zojer et autres
The vital cell cycle machinery is tightly regulated and alterations of its central signaling hubs are a hallmark of cancer. The activity of CDK6 is controlled by interaction with several partners including cyclins and INK4 proteins, which have been shown to mainly …
at
(code pays fourni par la source)
2024
article
OpenAlex
Alessia Schirripa, Sofie Nebenfuehr, Helge Schöppe, Markus Zojer et autres
The family of cyclin-dependent kinases (CDKs) comprises more than 20 serine/threonine kinases functioning in diverse cellular processes including cell-cycle progression and transcriptional regulation. Dysregulation of CDKs is directly linked to tumorigenesis, e.g. leukemic cells highly depend on CDK6, a pivotal component in …
at
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Belinda S. Schmalzbauer, Teresemary Thondanpallil, Gerwin Heller, Clio-Melina Sperl et autres
Background: Acute myeloid leukemia (AML) is a highly aggressive disease that comprises a heterogeneous group of genetically distinct subtypes. AML is initiated by leukemic cells, which are able to self-renew and give rise to malignant myeloid blasts. A key regulator and prognostic …
at, cz
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Lisa Scheiblecker, Sofie Nebenfuehr, Markus Zojer, Eszter Doma et autres
Background: The mammalian cell cycle is controlled by a complex signaling network that is frequently deregulated in cancer. Cyclin-dependent kinases (CDKs) are the key players in governing cell cycle progression. CDK6 and its close homologue CDK4 are responsible for driving the cell …
at
(code pays fourni par la source)
Accès ouvert
2022
article
OpenAlex
Belinda S. Schmalzbauer, Teresemary Thondanpallil, Gerwin Heller, Alessia Schirripa et autres
Cyclin-dependent kinase 6 (CDK6) represents a novel therapeutic target for the treatment of certain subtypes of acute myeloid leukaemia (AML). CDK4/6 kinase inhibitors have been widely studied in many cancer types and their effects may be limited by primary and secondary resistance …
at
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Gerwin Heller, Sofie Nebenfuehr, Florian Bellutti, Huriye Ünal et autres
CDK6 is frequently overexpressed in various cancer types and functions as a positive regulator of the cell cycle and as a coregulator of gene transcription. We provide evidence that CDK6 is involved in the process of DNA methylation, at least in ALL. …
at
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Sofie Nebenfuehr, Karoline Kollmann, Veronika Sexl
The regulation and function of cyclin-dependent kinase 6 (CDK6)- and cyclin-dependent kinase 4 (CDK4)-cyclin complexes are commonly altered with enhanced kinase activity found in hematopoietic malignancies, breast cancer and melanoma making CDK4 and CDK6 attractive targets for therapeutic interference. Although dual CDK4/6 …
at
(code pays fourni par la source)
Accès ouvert
2019
conference-abstract
OpenAlex
Sofie Nebenfuehr, Florian Bellutti, Karoline Kollmann, Matthias Farlik et autres
Background: Cyclin‐dependent kinase 6 (CDK6) together with its close homologue CDK4 enables the progression of cells through the early G1 phase of the cell cycle. CDK4/6‐cyclin D complexes phosphorylate members of the retinoblastoma (Rb) protein family, allowing for the release of E2F …
at, in
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Iris Z. Uras, Barbara Maurer, Sofie Nebenfuehr, Markus Zojer et autres
While significant progress has been made in the treatment of acute myeloid leukemia (AML), not all patients can be cured. Mutated in about 1/3 of de novo AML, the FLT3 receptor tyrosine kinase is an attractive target for drug development, activating mutations …
at
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Sofie Nebenfuehr, Florian Bellutti, Veronika Sexl
In cancer the activity of cyclin-dependent kinase 4-(CDK4) and cyclin-dependent kinase 6 (CDK6)-cyclin complexes are frequently altered with enhanced CDK6 expression found in hematopoietic malignancies. Our latest findings show a so far unknown role of Cdk6 during oncogene-induced stress and transformation. Therein …
at
(code pays fourni par la source)
Accès ouvert
2018
article
OpenAlex
Florian Bellutti, Anca-Sarmiza Tigan, Sofie Nebenfuehr, Marlies Dolezal et autres
.
at, de, us
(code pays fourni par la source)